DNA vaccine against amyloid-beta and tau

a technology of amyloid beta and amyloid beta, which is applied in the field of dna vaccines against amyloid beta and tau, can solve the problems of extremely weak effect of reducing tau deposition, and no dna vaccine is known to reduce a deposition and tau deposition simultaneously by means of a single molecul

Pending Publication Date: 2022-09-08
IMMUNOTHERAPY DEV INC
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The approach effectively induces antibodies against both Aβ and tau, leading to a significant reduction in brain Aβ and tau deposition, particularly phosphorylated tau, which is strongly neurotoxic, thus providing a promising treatment or prevention for Alzheimer's disease.

Problems solved by technology

From pathological examination, however, it has been reported that although anti-immunotherapy effectively reduces Aβ deposition, its effect of reducing tau deposition is extremely weak (Non Patent Literature 1: Boche, D. et al., Acta Neuropathol 120, 13-20).
At present, DNA vaccines against Aβ are known (Patent Literature 1: WO 2010 / 110408); however, no DNA vaccine is known that can reduce Aβ deposition and tau deposition simultaneously by means of a single molecule.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • DNA vaccine against amyloid-beta and tau
  • DNA vaccine against amyloid-beta and tau
  • DNA vaccine against amyloid-beta and tau

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0223]1. Construction of Recombinant Vector (Plasmid) Comprising DNAs Encoding IgL Sequence, Aβ, IgFc Sequence, and Tau

[0224](1) Amplification and Cloning of DNAs Encoding IgL Sequence and IgFc Sequence

[0225]To clone DNAs encoding an immunoglobulin κ leader (hereinafter “IgL”) sequence and an immunoglobulin Fc (hereinafter “Fc” or “IgFc”) sequence, human peripheral blood-derived mRNA was used as a material to synthesize cDNAs using ReverTra Ace-α- (TOYOBO, Tokyo, Japan). Primers comprising the 5′ or 3′ end of the nucleotide sequence encoding each sequence and having an appropriate restriction enzyme site (IgL: Bam HI or Xho I; IgFc: Kpn I or Not I) were designed and used to amplify DNAs encoding (or DNAs comprising DNAs encoding) human IgL sequence (SEQ ID NO: 32) and human IgFc sequence using KOD-plus- (Toyobo, Tokyo, Japan). Although the original human IgFc sequence comprises three codons each encoding a cysteine residue near the 5′ end, these codons were each modified to encode a...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

An object of the present invention is to provide a vaccine that can simultaneously reduce Aβ deposition and tau deposition in the brain by means of a single molecule. The present invention provides a recombinant vector comprising DNA encoding amyloid-β, DNA encoding an immunoglobulin Fc sequence, and DNA encoding tau.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS[0001]This application is a Continuation of copending application Ser. No. 15 / 578,123, filed on Nov. 29, 2017, which is a 35 U.S.C. 371 National Stage of PCT International Application No. PCT / JP2016 / 081038 on Oct. 20, 2016, which claims the benefit under 35 U.S.C. § 119(a) to Patent Application No. 2015-207888, filed in Japan on Oct. 22, 2015, all of which are hereby expressly incorporated by reference into the present application.TECHNICAL FIELD[0002]The present invention relates to DNA vaccines against amyloid-β and tau.BACKGROUND ART[0003]Alzheimer's disease is a disease in which moderate to severe cerebral atrophy is grossly visible in the frontal association cortex, temporal lobe, and hippocampal region, and is characterized by three major microscopic findings, i.e., senile plaques (amyloid-β (Aβ) deposition), neurofibrillary tangles (hyperphosphorylated tau deposition), and neuronal loss.[0004]There are many reports that amyloid accumulat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & AuthorityApplications(United States)
IPC IPC(8): A61K39/00A61K31/713C12N15/85A61K31/711C12N15/63C07K14/47
CPCA61K39/0007A61K31/713C12N15/85A61K31/711C12N15/63C07K14/4711A61K2039/53C07K2319/30A61P25/28
InventorMATSUMOTO
OwnerIMMUNOTHERAPY DEV INC